Department of Clinical Medicine, Jiangxi Health Vocational College of China.
Second Affiliated Hospital of Nanchang University.
Medicine (Baltimore). 2021 Feb 19;100(7):e24414. doi: 10.1097/MD.0000000000024414.
Coronary heart disease is a serious cardiovascular disease. There is coronary atherosclerosis, resulting in lumen stenosis, blockage, and then the symptoms of insufficient blood supply and hypoxia in the myocardium. Chronic heart failure is a kind of syndrome with abnormal ventricular filling and ejection function, which is the final stage of the development of coronary heart disease. At present, the treatment plan of Western medicine can significantly reduce the hospitalization rate, but it is still not satisfactory for the prognosis and mortality of patients. Shenfu injection has advantages in the treatment of heart failure in patients with coronary heart disease, but there is a lack of standard clinical studies to verify it, so the purpose of this randomized controlled study is to evaluate the efficacy and safety of Shenfu injection combined with sodium nitroprusside in the treatment of chronic heart failure in patients with coronary heart disease.
This is a prospective randomized controlled trial to study the efficacy and safety of Shenfu injection combined with sodium nitroprusside in the treatment of chronic heart failure in patients with coronary heart disease. The patients will be randomly divided into a treatment group and the control group according to 1:1, in which the treatment group is treated with Shenfu injection combined with sodium nitroprusside, and the control group is treated with sodium nitroprusside alone. Both groups will be treated with standard treatment for 7 days and followed up for 30 days to pay attention to their efficacy and safety indexes. The observation indexes include TCM syndrome score, N-terminal pro-brain natriuretic peptide, left ventricular ejection fraction, brain natriuretic peptide, left ventricular end-systolic diameter, left ventricular end-diastolic diameter, stroke volume, adverse reactions and so on. We will use SPSS 25.0 software for data analysis.
This study will evaluate the efficacy and safety of Shenfu injection combined with sodium nitroprusside in the treatment of chronic heart failure in patients with coronary heart disease. The results of this experiment will provide a clinical basis for Shenfu injection combined with sodium nitroprusside in the treatment of chronic heart failure in coronary heart disease.
DOI 10.17605/OSF.IO/4KNG3.
冠心病是一种严重的心血管疾病。存在冠状动脉粥样硬化，导致管腔狭窄、阻塞，进而出现心肌血液供应不足和缺氧的症状。慢性心力衰竭是一种心室充盈和射血功能异常的综合征，是冠心病发展的终末阶段。目前，西医治疗方案能显著降低住院率，但对患者的预后和死亡率仍不满意。参附注射液在冠心病心力衰竭的治疗中有优势，但缺乏标准的临床研究来验证，因此本随机对照研究旨在评价参附注射液联合硝普钠治疗冠心病慢性心力衰竭的疗效和安全性。
这是一项前瞻性随机对照研究，旨在研究参附注射液联合硝普钠治疗冠心病慢性心力衰竭的疗效和安全性。患者将按照 1:1 的比例随机分为治疗组和对照组，其中治疗组采用参附注射液联合硝普钠治疗，对照组采用硝普钠单独治疗。两组均采用标准治疗方案治疗 7 天，并随访 30 天，以关注其疗效和安全性指标。观察指标包括中医证候评分、N 末端脑利钠肽前体、左心室射血分数、脑钠肽、左心室收缩末期直径、左心室舒张末期直径、每搏输出量、不良反应等。我们将使用 SPSS 25.0 软件进行数据分析。
本研究将评价参附注射液联合硝普钠治疗冠心病慢性心力衰竭的疗效和安全性。该实验的结果将为参附注射液联合硝普钠治疗冠心病慢性心力衰竭提供临床依据。
DOI 10.17605/OSF.IO/4KNG3。
